Original article

Neoadjuvant chemotherapy or adjuvant chemotherapy is similarly beneficial for locally advanced gastric cancer patient

*‡Sah Birendra Kumar, ‡Yu Zhenjia, Lu Sheng, Zhu Zhenglun, Li Jian, *Li Chen*, Yan Min, *Zhu Zhenggang

Running title: NAC or AC is similarly effective for gastric cancer

Authors

*Birendra Kumar Sah, MD/Ph D

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Postal add: 197 Ruijin Er Road, Shanghai-200025, China

Contact no. : Ph: 0086-21-64370045 ext 671302

Email: rjsurgeon@hotmail.com

ORCID ID: 0000-0002-7415-960X

Yu Zhenjia MD/Ph D (Co-first author)

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

Li Jian MD/PhD

Clinical Research Center

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Lu Sheng MD

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

Zheng Yanan MD/Ph D

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

Zhu Zhenglun MD/Ph D

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

*Li Chen, MD/Ph D

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

Yan Min, MD

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, China.

*Prof. Zhu Zhenggang, MD/Ph D, FACS

Department of General Surgery, Gastrointestinal Surgery Unit

Ruijin Hospital Shanghai Jiao Tong University School of Medicine

Shanghai Key Laboratory of Gastric Neoplasms

Shanghai Institute of Digestive Surgery

Shanghai, China.

*Corresponding author

‡ These authors contributed equally

Abstract

Background: Different types of neoadjuvant chemotherapy regimens have been compared for gastric cancer, mostly in terms of radiological downgrading or pathological tumor regression, however, there was no large-scale multicenter RCT study that conducted head-to-head comparison for overall survival rate between the perioperative or neoadjuvant chemotherapy(NAC) and postoperative or adjuvant chemotherapy(AC). We explored whether the five years overall survival rate is greater in the patients who had perioperative chemotherapy plus surgery compared to those who underwent surgery first and postoperative chemotherapy.

Methods: Altogether 77 patients with the clinical diagnosis of cTNM stage III were included. Five years overall survival rates(OS) were compared between the patients who underwent neoadjuvant chemotherapy plus surgery (NAC) and the patients who had surgery first plus adjuvant chemotherapy (AC). A propensity score matching was applied for adjusting the disparity between the two groups. A Kaplan-Meier plot was created for survival analysis, Log Rank method was used to compare the difference in OS.

Results: A total of 34 patients were in the NAC group and 43 patients in the AC group. There was no significant difference in age (median 64 vs 66 years), cTNM staging, and extent of gastrectomy between the two groups ($p<0.05$). The median follow-up time was 58 months (range of 53-65 months). Five years

of overall survival (OS) for the patients in the NAC group and AC group were 61.8% and 73.5% respectively. There was no statistical difference between the two groups in five years' overall survival rates ($p>0.05$). There was no significant difference in the severity grading of postoperative complications between the two groups ($p>0.05$).

Conclusions: There was no significant difference in five years overall survival rate between the patients who had perioperative chemotherapy plus surgery compared to those who had surgery first plus postoperative chemotherapy. A well-controlled prospective study is necessary to reconfirm whether perioperative chemotherapy is superior to postoperative chemotherapy for gastric cancer patients.

Keywords: gastric cancer; neoadjuvant chemotherapy; adjuvant chemotherapy,

Introduction

The treatment strategy for gastric cancer includes surgery and adjuvant therapy. In terms of survival benefits, the extent of surgery is no more focus of new research, and there are clear suggestions that chemotherapy is beneficial for locally advanced diseases. After the publication of results from the MAGIC trial by David Cunningham in 2006, a new trend started for the research of neoadjuvant chemotherapy (1). However, it should be noted that the MAGIC trial was the comparison between a group of patients who underwent perioperative chemotherapy (preoperative and postoperative chemotherapy) plus surgery with the group of patients who had surgery only, i.e. a group of patients did not receive chemotherapy at all (1). And in 2014, Sung Hoon Noh published the result of another famous trial, the CLASSIC trial, where they compared a group of patients who had surgery only with a group of patients who had surgery and received postoperative chemotherapy (2). The 5 years overall survival rate of the patients who had perioperative chemotherapy plus surgery was significantly higher than the patients who underwent surgery only in the MAGIC trial. And the five years OS was significantly higher in the patients who had surgery and postoperative chemotherapy compared to those with surgery only in the CLASSIC trial. Despite the demographic differences between the two trials, these results at the very least suggest that the chemotherapy was beneficial for gastric cancer patients because the 5 years OS was increased in the patients who received either perioperative

chemotherapy or postoperative chemotherapy (1, 2). There was no large-scale multicenter RCT study that conducted head to head comparison between perioperative chemotherapy and postoperative chemotherapy. And only recently, a multicenter RCT from China, the RESOLVE trial published their result in Lancet which compared the perioperative chemotherapy with postoperative chemotherapy, but the patients in two groups received different chemotherapy regimens (3). This study demonstrated that in the patients who underwent surgical treatment, the 3 years of DFS is significantly better in the patients who received perioperative chemotherapy with SOX regimen compared to those who received postoperative chemotherapy with CAPOX regimen (59.4% versus 51.1%). The 3-year DFS for the patients who received postoperative chemotherapy with the SOX regimen was 56.5% (3). However, it is still not clear whether the perioperative SOX is also superior to postoperative SOX.

Besides, there are still blunt disagreements between Eastern and Western researchers over the indication of neoadjuvant chemotherapy (4-7). One reasonable argument is that preoperative evaluation of the tumor (cT and cN) is not consistent with pathological pT and pN. More than 10 percent of stage I patients were misdiagnosed as a late stage in a large-scale Japanese study (8). We explored whether the five years overall survival rate is greater in the patients who had perioperative chemotherapy plus surgery compared to those who underwent surgery first and postoperative chemotherapy.

Methods

Only pathologically confirmed gastric cancer patients who were preoperatively diagnosed with cTNM stage III (cT3 or T4 and N1 or N2 or N3 and M0) and underwent radical surgery (total or partial gastrectomy with D2 lymphadenectomy) were included in this study. All the patients were treated in the year 2018 at Ruijin Hospital, Shanghai Jiaotong University School of Medicine, which is a referral center for gastric cancer patients in China. Patients were divided into two groups, i.e. perioperative chemotherapy plus surgery group (NAC) and surgery first plus chemotherapy group (AC). Because of the retrospective nature of the study, we empirically excluded 403 patients for different reasons that we consider may adversely affect the analysis (Supplementary Table 1). Our previous study for elderly patients suggested that there was a difference in overall survival between the patients who had total gastrectomy and the patients who had partial gastrectomy; therefore, we applied the propensity score matching method to eliminate the discrepancy between the two groups. Altogether 172 cases were included in the propensity score matching for cT staging, cN staging, and types of gastrectomy. Among them, 98 cases were matched and approached for follow-up. Finally, only 77 patients were included in the final analysis, 21 patients were excluded due to insufficient or unconfirmed data for survival time. Postoperative morbidity and mortality were recorded according to the Clavien-Dindo grading (9). Overall survival (OS) time in this study is the time

from the date of surgery to death from any cause. The data for Relapse-free survival (RFS) was not accurately available, thus not analyzed in this study.

Statistical analysis

The statistical analysis was performed with Statistical Package for Social Science (SPSS) version 22.0 for Windows (SPSS, Inc., Chicago, Illinois). Nonparametric methods were used to analyze data with an abnormal distribution. The continuous data are expressed as the median and range, the Mann-Whitney U test was used for continuous data. The chi-square test and Fisher's exact test were used to compare the differences between the two groups as appropriate. Survival data were presented as the length of overall survival (OS), in months. A Kaplan-Meier plot was created for survival analysis, Log Rank method was used to compare the OS rates. Cox regression analysis was used to identify the risk factors for OS. A p-value of less than 0.05 was considered statistically significant.

Results

Altogether 77 patients were included in this study; 34 patients in the NAC group and 43 patients in the AC group. There was no significant difference in demographic variables between the patients of the two groups ($p>0.05$) including the preoperative clinical staging of the gastric cancer (cT stage and cN stage), and the extent of gastrectomy (Table 1). Patients received the established chemotherapy regimens, among 34 patients in the NAC group, 13 patients received SOX, 9 patients received EOX, 7 patients received FLOT,

and 5 patients received SOX-A. Patients in both groups received postoperative chemotherapy for six months, there was no significant difference in the completion of postoperative adjuvant chemotherapy between the two groups ($p>0.05$). Details on the adverse effects of the chemotherapy were not described due to the lack of accurate data due to the retrospective nature of the current study. The median follow-up time was 58 months (range of 53-65 months). The estimated five years of overall survival (OS) rate for the patients in the NAC group and AC group were 61.8% and 73.5% respectively. There was no statistical difference between the two groups in five years' overall survival rates ($p>0.05$). There was no statistical difference in the severity grading of postoperative complications (Table 2) and length of postoperative stay between the two groups ($p>0.05$). One patient in the NAC group achieved pCR, there were 9 patients in AC groups with pTNM stage I (Table 3).

Discussion

For the last three decades, it has been reported that more than 2300 articles have been published regarding neoadjuvant chemotherapy for gastric cancer (10), however very few of them were widely accepted, and if there is only one article should be remembered as a pioneering concept for neoadjuvant chemotherapy, it is the MAGIC trial (1), despite not being the first one to report. And despite exponential growth in terms of publications on neoadjuvant chemotherapy, most of these studies are mainly conducted in a few countries. China, the USA, and Japan scored top three countries for these studies (10).

And there is still no joint agreement or a hard-line guideline to recommend that neoadjuvant chemotherapy is mandatory for gastric cancer. This may be due to conflicting results from different centers (6,7,11-13) or perhaps somewhat deficient study design in the past, and none of them answered the fundamental question that perioperative or neoadjuvant chemotherapy plus surgery is superior to surgery first plus adjuvant chemotherapy(1,2,3). And most of the research for neoadjuvant chemotherapy is focused on comparing the efficacy between different types of chemotherapy regimens, mainly focused in terms of radiological or pathological response to the therapy (15, 16). Al-Batran SE. published the initial results of the FLOT 4 trial and demonstrated that the FLOT regimen was better than ECF or ECX in terms of pathological regression and tolerance (15). Sah BK published the initial reports of comparative results of pathological efficacy between the triplet chemotherapy FLOT and the doublet chemotherapy SOX. There was no statistical difference between neoadjuvant FLOT and SOX in terms of tumor regression grading, however, the five years overall survival rate is not published yet (16). Besides, we did not find any study which claimed the superiority of NAC over AC in terms of overall survival, even in the final results of the FLOT 4 trial in 2019, the five years overall survival rate was much lower than those reported in the CLASSIC trial (2, 17). The main concern for neoadjuvant chemotherapy in Japan is the accuracy of clinical TNM staging (8), and it should be noted that 20.9 percent of patients in the surgery first groups were pTNM stage I in this study. And because it would

have impacted the comparison of OS, we further compared the OS between two groups excluding the pathological stage I and II, though it is not required because a similar probability of misdiagnosis is anticipated in the NAC group too. Nonetheless, there was no difference in OS between the two groups even after excluding these early-stage tumors (Fig.2).

There are several shortcomings in this study, mainly due to retrospective analysis; the number of patients finally included in this study is quite small to achieve any convincing conclusion. We excluded hundreds of cases for valid reasons (Supplementary Table 1), which was intended to eliminate the disparity between the two groups. There were no data on the adverse effects of chemotherapy; we did not analyze it as the focus of this study was to compare the overall survival rate, besides many adverse effects were not recorded in standard forms. Besides, there were several types of chemotherapy regimens, though the types of chemotherapy might have somehow influenced the result but previous studies have shown that CAPOX and SOX regimens were similarly effective for gastric cancer (3). And even the SOX was similarly effective as the FLOT regimen in terms of pathological regression (16). Nevertheless, despite being a small-scale retrospective study, the result of this study is quite interesting and it raises the fundamental question that whether neoadjuvant chemotherapy is beneficial because the CLASSIC trial has shown that 5 years overall survival rate is 78% for the patients who had surgery first and received postoperative or adjuvant

chemotherapy (AC). So any rationale for alteration to this treatment should only be considered for two basic reasons, either to increase the percentage of overall survival rate or decrease the toxic side effects of chemotherapy. By the analysis of this data, we neither deny the use of neoadjuvant chemotherapy nor question its efficacy in terms of overall survival. However, at the very least it concludes that chemotherapy either perioperative or postoperative, is similarly effective. And whether the addition of preoperative chemotherapy is beneficial in terms of OS is still questionable. And there is still a place for a better-designed study to be conducted. Perhaps the next study should focus on the non-inferiority test, and not on the superiority test between two modes. If the NAC is similarly effective to AC then it would be better to conduct a large-scale study that compares total preoperative chemotherapy plus surgery (no postoperative chemotherapy) with surgery first plus postoperative chemotherapy.

Despite being no concrete data to support this, we can easily assume that preoperative chemotherapy is better in terms of completion of required cycles compared to postoperative chemotherapy after the major surgery. Due to postoperative complications, a certain number of patients can not start adjuvant chemotherapy on time or are simply unable to receive the chemotherapy.

The result of this study by no means negates the need for further study on neoadjuvant chemotherapy. However, attention is necessary for designing

future studies by understanding the limitations of conventional chemotherapy. And whether the addition of immune therapy or targeted therapy is beneficial for long-term survival is still unknown.

Conclusion

There was no statistical difference in five years overall survival rate between the patients who had perioperative chemotherapy plus surgery compared to those who had surgery first plus postoperative chemotherapy. A well-controlled prospective study is necessary to reconfirm whether perioperative chemotherapy is superior to postoperative chemotherapy for gastric cancer patients.

Declaration

Ethics approval and consent to participate

The Ethics Committee of Ruijin Hospital approved this study and waived the individual informed consent due to the retrospective analysis. The study was carried out in conformity with the Declaration of Helsinki (as revised in 2013)

Consent for publication

The manuscript does not contain any individual data which identifies the patient included in this study.

Patients and the public

Patients and the public were not involved in the design of this study due to the retrospective nature of this research.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

The overall costs of this research will be funded by grants from the National Natural Science Foundation of China No. 81871904 (ZG Zhu), and No.82103396(ZJ Yu).

Author contributions

BKS designed the study, collected the patient data, and drafted the

manuscript.ZJY followed up with patients for overall survival and revised the manuscript. SL assisted in data collection from the central database of the unit.YNZ and ZLZ revised the drafts of the manuscript.CL and ZGZ participated in the design of the study and critically revised the drafts of the manuscript. All authors meet the criteria for publication; all authors have read and approved the final manuscript.

Acknowledgments

The authors thank all the clinicians in the gastrointestinal department for their support to conduct this study. And especially thanks to Mrs. Qin Yu for recording the data in the central database.

References

1. Cunningham D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.

2. Noh SH et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1389-96.

3. Zhang X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-1092.

4. Reddavid R. et al. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol. 2018 Jan 14;24(2):274-289.

5. Iwasaki Y. et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021 Mar;24(2):492-502.

6. Katayama H. et al. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer. 2019 Nov;22(6):1301-1307.

7. Takahari D. et al. Stomach Cancer Study Group of the Japan Clinical Oncology Group. Long-term outcomes of preoperative docetaxel with cisplatin

plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002). Gastric Cancer. 2020 Mar;23(2):293-299.

8. Fukagawa T. et al. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018 Jan;21(1):68-73.

9. Dindo D. et al. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.

10. Tianxing Chen et al. Visual analysis of the research hotspots in neoadjuvant therapy for patients with gastric cancer. Front. Gastroenterol. 28 April 2023; Sec. Gastroenterology and Cancer Volume 2 2 - 2023

11. Li, W. et al. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J. Gastroenterol. 16, 5621–5628 (2010).

12. Ronellenfitsch, U. et al. Perioperative chemo (radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. CD008107 (2013).

13. Eto, K. et al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer 21, 703–709 (2018).

15. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et

al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697-708.

16. Sah BK et al. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020 Nov 30;11(1):6093.

17. Al-Batran SE. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-1957.

Table 1 Demographic Data

Parameter		NAC	DS	P Value
Sex	Male	26(76.5)	26(60.5)	0.106
	Female	8(23.5)	17(39.5)	
Age (years)	Median(Range)	64(38-77)	66(44-86)	0.531
Body mass index	Median	22.42	22.18	0.573
Site of tumor	Proximal	8(23.5)	9(20.9)	0.227*
	Body	11(32.4)	7(16.3)	
	Distal	15(44.1)	25(58.1)	
	Total	0	2(4.7)	
cT stage	T3	3(8.8)	4(9.3)	1.000
	T4	30(88.2)	37(86.2)	
	T4b	1(2.9)	2(4.7)	
cN stage	N1	2(5.9)	1(2.3)	0.709
	N2	22(64.7)	27(62.8)	
	N3	10(29.4)	15(34.9)	
Type of Gastrectomy	Distal	17(50.0)	23(53.5)	0.821
	Total	17(50.0)	20(46.5)	
Postop Chemo	Yes	26(76.5)	31(72.1)	0.307
	No	5(14.7)	11(25.6)	
	Unknown	3(8.8)	1(2.3)	

*Fisher's Exact Test

Table 2 Postoperative Complications

Complication	NAC plus Surgery	Direct Surgery
Grade 0- I	27(79.4)	21(72.4)
Grade II	6(17.6)	7(24.1)
Grade IIIa	1(2.9)	0
Grade IVa	0	1(3.4)
Grade V	0	0

Table 3 Postoperative Pathology

Parameter	Stage	NAC plus Surgery	Direct Surgery
ypTNM	pCR	1(2.9)	
	I	3(8.8)	
	II	11(32.4)	
	III	19(55.9)	
pTNM	I		9(20.9)
	II		5(11.6)
	III		29(67.4)

Figure legends

Fig.1 Kaplan-Meier (K-M) Plot for OS



Fig.2 Kaplan-Meier (K-M) Plot for OS (only pTNM III in Direct Surgery group)



Supplementary Table 1

Reason for exclusion	Number
No standard data for preoperative CT	22
Preoperative diagnosis of T1, T2, N0	192
Clinical suspicion of M1 or MX	48
Combined multiorgan resection	41
Robotic surgery	8
Thoraco-abdominal approach for the surgery	3
Surgery for remnant gastric cancer	2
Preoperative chemotherapy intended for conversion therapy	2
Unconventional chemotherapies	12
Neuroendocrine carcinoma	6
Squamous cell carcinoma	2
No R0 surgery	10
Surgery performed by inexperienced surgeons(<30surgeries)	55